Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) has 1 pending office action in the Chemistry & Materials technology area. This action is assigned to 1 distinct examiner, MUI, CHRISTINE T. As the examiner for the portfolio, MUI, CHRISTINE T is responsible for the 1 busiest examiner pending action.
The company's prosecution is currently limited to 1 distinct art unit. This suggests a focused technical scope for the company's active filing. The 1 pending office action and 1 distinct examiner constitute the full scope of the company's active prosecution at this time.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| MOAZZAMI, NAGHMEH NINA | 1 | 72.0% | +49.3% |
| LE, AUSTIN Q | 1 | 49.7% | +31.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18510940 | FUSION PROTEINS OF PD-1 AND 4-1BB | OUSPENSKI, ILIA I | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268948 | APPLICATION OF CRISPR/CAS13 FOR THERAPY OF RNA VIRUS AND/OR BACTERIUM INDUCED DISEASES | MOAZZAMI, NAGHMEH NINA | 9d |
| 18510940 | FUSION PROTEINS OF PD-1 AND 4-1BB | OUSPENSKI, ILIA I | — |
| 18046737 | METHODS AND SYSTEMS FOR FABRICATING BIOSENSORS | LE, AUSTIN Q | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1652 | 1 |
| 1796 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18510940 | FUSION PROTEINS OF PD-1 AND 4-1BB | OUSPENSKI, ILIA I | 1644 | §102§112 | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18268948 | APPLICATION OF CRISPR/CAS13 FOR THERAPY OF RNA VIRUS AND/OR BACTERIUM INDUCED DISEASES | MOAZZAMI, NAGHMEH NINA | 1652 | §103DP | Final Rejection | 9d | Pending | Jun 21, 2023 |
| 18046737 | METHODS AND SYSTEMS FOR FABRICATING BIOSENSORS | LE, AUSTIN Q | 1796 | §103 | Final Rejection | — | Pending | Oct 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial